New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 2, 2013
06:43 EDTBCRC.R. Bard upgraded to Overweight from Neutral at JPMorgan
JPMorgan upgraded C.R. Bard based on expectations for a resolution of the Gore patent litigation, a positive outcome in the LEVANT 2 trial, and higher earnings revisions. Price target raised to $116 from $110.
News For BCR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 29, 2015
17:59 EDTBCRC.R. Bard sees FY15 EPS ex-items $8.95-$9.05, consensus 9.22
Subscribe for More Information
17:54 EDTBCRC.R. Bard sees Q1 EPS $2.04-$2.08, consensus $2.13
Sees Q1 sales growth 4%-5%. Guidance provided in Q4 earnings conference call.
16:16 EDTBCRC.R. Bard reports Q4 adjusted EPS $2.29, consensus $2.24
Subscribe for More Information
15:37 EDTBCRNotable companies reporting after market close
Subscribe for More Information
January 20, 2015
06:32 EDTBCRC.R. Bard upgraded to Neutral from Underweight at JPMorgan
JPMorgan upgraded C.R. Bard to Neutral on expectations drug-coated balloons growth in the U.S. is likely to exceed consensus expectations. The firm raised its price target for shares to $178 from $162.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use